Oral News and Research

RSS

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis.

10 Sep 2012

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

BioLineRx, a biopharmaceutical development company, announced today that BL-7010, an orally available treatment for celiac disease, was found to be safe and well tolerated in pre-clinical studies conducted to date.

10 Sep 2012

New oral antiseptic spray effective in killing 99.9% of infectious airborne germs

University Hospitals Case Medical Center clinical researchers will present findings about a one-two punch to prevent colds and flu in San Francisco at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Sept. 9.

10 Sep 2012

Novel surgical technique removes invasive facial tumor, recreates functional lower jaw and mouth

Using a novel surgical approach, it's possible to rebuild a functional lower jaw and mouth, and preserve a patient's ability to eat and speak after removing an invasive facial tumor, according to a new report from Henry Ford Hospital in Detroit.

10 Sep 2012

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

Kalidex announces presentation of data on KPI-10 against MDR strains at ICAAC

Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.

7 Sep 2012

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Durata Therapeutics today announced that it has completed its target enrollment for DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response"), one of two ongoing, global, Phase 3 clinical trials of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (abSSSI).

7 Sep 2012

Vitamin D supplements have unintended lipid consequences

Correcting vitamin D levels in individuals at risk for cardiovascular disease may have detrimental effects on their lipid profiles, report researchers.

6 Sep 2012

WOEST: Dual antiplatelet therapy more effective than triple

Dual antiplatelet therapy with clopidogrel and an oral anticoagulant reduces bleeding and mortality more effectively than triple therapy including aspirin, researchers say.

6 Sep 2012

Reduced NF-κB expression linκed to postradiation oral mucosa vulnerability

The fragility of oral mucosa after radiotherapy for oral squamous cell carcinoma may be due to the inhibition of the DNA transcriptor protein nuclear factor κappa-light-chain-enhancer of activated B cells, show study findings.

6 Sep 2012

Cholera vaccine offers herd immunity, study from Zanzibar shows

"Cholera vaccine gives indirect protection to unvaccinated people in communities where a substantial fraction of the population gets the vaccine," according to a study from the island of Zanzibar in East Africa, published in the Lancet on Tuesday, NPR's "Shots" blog reports.

6 Sep 2012

Key facts about polycystic ovary syndrome

September marks Polycystic Ovary Syndrome (PCOS) awareness month and with this condition affecting millions of women in the world, there are some key facts about the condition to highlight that can affect a women's fertility when suffering with the disorder.

6 Sep 2012

Targacept plans to pursue development of TC-5214 for overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it plans to pursue development of TC-5214 as a treatment for overactive bladder (OAB).

6 Sep 2012

Roundup: Cancer drug cost equity bill sitting on Calif. Gov's desk; Mass. cost-containment law could harm provider credit ratings

Out-of-pocket costs for cancer drugs can vary dramatically depending on whether the medications are administered through pill form or intravenous infusion. Newer oral drugs, which can be taken at home and often have fewer side effects than older drugs, can cost patients thousands of dollars a month, while receiving chemotherapy through an IV in an infusion center typically amounts to a standard co-payment for an office visit.

6 Sep 2012

Unemployment barrier to antidiabetic medication adherence

People with diabetes are less likely to adhere to their oral antidiabetic medication if they are unemployed, report researchers.

5 Sep 2012

Study questions use of vitamin D supplements to improve cholesterol

Vitamin D has been touted for its beneficial effects on a range of human systems, from enhancing bone health to reducing the risk of developing certain cancers. But it does not improve cholesterol levels, according to a new study conducted at The Rockefeller University Hospital.

From Quest Diagnostics 5 Sep 2012

VOA examines global polio eradication efforts

VOA News reports on global efforts to eradicate polio, writing, "Experts say with India now polio-free and the total number of cases at the lowest level ever, this is an opportunity to change history and eradicate the disease entirely."

5 Sep 2012

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.

5 Sep 2012

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it has initiated the first of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel blocker for the treatment of chronic neuropathic pain indications.

5 Sep 2012

Oral News and Research

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

New oral antiseptic spray effective in killing 99.9% of infectious airborne germs

Novel surgical technique removes invasive facial tumor, recreates functional lower jaw and mouth

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

Kalidex announces presentation of data on KPI-10 against MDR strains at ICAAC

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Vitamin D supplements have unintended lipid consequences

WOEST: Dual antiplatelet therapy more effective than triple

Reduced NF-κB expression linκed to postradiation oral mucosa vulnerability

Cholera vaccine offers herd immunity, study from Zanzibar shows

Key facts about polycystic ovary syndrome

Targacept plans to pursue development of TC-5214 for overactive bladder

Roundup: Cancer drug cost equity bill sitting on Calif. Gov's desk; Mass. cost-containment law could harm provider credit ratings

Unemployment barrier to antidiabetic medication adherence

Study questions use of vitamin D supplements to improve cholesterol

VOA examines global polio eradication efforts

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News